Accuray (NSDQ:ARAY) announced that it promoted executive Suzanne Winter to president, effective as of July 1, 2021.
Winter, who previously served as Sunnyvale, Calif.-based Accuray’s chief commercial officer and SVP of R&D & medical & scientific affairs, will continue to report to CEO Joshua Levine.
“Suzanne has had a significant impact on Accuray’s product portfolio and commercial momentum since joining the company. She is a leader who has a proven track record of building performance-oriented commercial organizations. We believe that her strategic leadership of Accuray’s commercial and R&D teams has successfully positioned the company for accelerated revenue growth,” Levine said in a news release. “In her expanded role, Suzanne will focus on the day-to-day business operations of the company, which will allow me to focus on growing Accuray’s external strategic collaborations and business development opportunities.
“I look forward to continuing to partner with Suzanne in her new role and I have every confidence she will effectively lead our global team as we continue to serve our customers and the patients they treat.”
Winter’s role includes responsibilities with commercial operations and R&D, as well as overseeing the company’s global manufacturing operations, service organization and quality and regulatory affairs organizations.
Before Accuray, Winter served as group VP of the Americas region in Medtronic’s diabetes business segment. She also served as GM of GE Healthcare’s detection and guidance solutions operations.
“I’m truly honored to be named president and am looking forward to contributing to the work of this amazing company and building on the momentum we’ve achieved. We’ve established a bold new vision for the company that we believe will be transformational for our customers, their patients and our business,” Winter said. “I continue to be inspired by our passionate global team and am committed to delivering on our robust innovation pipeline so that we improve the lives of patients diagnosed with cancer and neurologic conditions around the world. I’m excited about our business and the opportunities I believe are in front of us.”
